

Special Issue

Progress in Nanoformulations for Nanomedicine

Message from the Guest Editors

The discovery and characterization of new therapeutic targets and strategies are a permanent process for effective translational medicine and health promotion. This Special Issue aims at reporting original biochemical compounds (cyclic peptides, peptide hormones, lipopeptides, peptide conjugates, nucleic acid-based drugs), phytoextracts, antibody–drug conjugates, biomarkers of disease, vaccines and their mode of isolation, identification, synthesis and purification followed by their physical-chemical, molecular and pharmacological characterizations. This SI is open for the publication of studies conducted at the basic science level and preclinical studies. We cordially invite research scholars (e.g., students, pharmacists, industrials, biologists, nanotechnologists, bioengineers, physicians) from all around the world to consider submitting their work, should it be original research, review articles or comprehensive preclinical studies that address the challenges in bringing biological agents or novel targeted theranostic strategies through drug compound identification, development and potential translation from bench to bedside.

Guest Editors

Prof. Dr. Farid Menaa

Departments of Nanomedicine and Translational Medicine,
Fluorotronics-CIC, San Diego, CA 92037, USA

Dr. Mohamed Skiba

Associate Professor, UFR Medecine-Pharmacie, Pharmacie Galénique
et de Biopharmacie, 22 Bd Gambetta, CEDEX, 76183 Rouen, France

Deadline for manuscript submissions

closed (15 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/131322

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).